There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Adicet Bio (ACET – Research Report), Jasper Therapeutics (JSPR – Research Report) and Lucid Diagnostics (LUCD – Research Report) with bullish sentiments.
Adicet Bio (ACET)
JonesTrading analyst Soumit Roy maintained a Buy rating on Adicet Bio today and set a price target of $6.00. The company’s shares closed last Monday at $1.49, close to its 52-week low of $1.10.
According to TipRanks.com, Roy is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adicet Bio with a $9.20 average price target.
See the top stocks recommended by analysts >>
Jasper Therapeutics (JSPR)
In a report released today, Tim Chiang from Capital One Financial assigned a Buy rating to Jasper Therapeutics, with a price target of $55.00. The company’s shares closed last Monday at $21.60.
According to TipRanks.com, Chiang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jasper Therapeutics with a $67.00 average price target, which is a 214.7% upside from current levels. In a report issued on May 6, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $65.00 price target.
Lucid Diagnostics (LUCD)
In a report released today, Michael Matson from Needham reiterated a Buy rating on Lucid Diagnostics, with a price target of $2.50. The company’s shares closed last Monday at $0.93.
According to TipRanks.com, Matson is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Lucid Diagnostics with a $3.83 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACET:
